熱門資訊> 正文
Adittext和Evofem修改合并协议
2024-09-09 21:16
- Aditxt (NASDAQ:ADTX) and Evofem Biosciences (OTCQB:EVFM) on Monday said that they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger under which Aditxt intends to acquire Evofem.
- Under the Second Amendment, the parties have extended the dates by which Aditxt shall complete the remaining $3 million in funding to Evofem through the purchase of 3,000 shares of Evofem’s F-1 Preferred Stock.
- Aditxt will provide $1.5 million of financing by September 30, 2024, and an additional $1.5 million by October 31, 2024.
- Both companies continue to work collaboratively to align strategic priorities and expect to close the transaction in the fourth quarter of 2024.
- EVFM +3.09% premarket to $0.01.
- Source: Press Release
More on Aditx Therapeutics, Evofem Biosciences, etc.
- Aditxt sells 1.13M shares at $1.06 in registered direct offering
- Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
- Financial information for Aditx Therapeutics
- Financial information for Evofem Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
